Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in Mult Scler Retrieve available abstracts of 397 articles: HTML format

Single Articles

July 2025
1. LEBRUN-FRENAY C, Okuda DT
   High-risk populations should be screened for multiple sclerosis: No.
   Mult Scler. 2025 Jul 8:13524585251353025. doi: 10.1177/13524585251353025.
   PubMed    
   
   
   
2. BECZEK A, Landt EM, Magyari M, Storr LK, et al
   Assessing the association between mortality and clinical follow-up visits in multiple sclerosis.
   Mult Scler. 2025 Jul 7:13524585251353079. doi: 10.1177/13524585251353079.
   PubMed     Abstract available
   
   
   
3. BOFFA G, Genchi A, Mariottini A, Brittain G, et al
   Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
   Mult Scler. 2025 Jul 7:13524585251349129. doi: 10.1177/13524585251349129.
   PubMed     Abstract available
   
   
   
4. AFFINITO G, Moccia M, Lanzillo R, Marrie RA, et al
   Neural networks to estimate multiple sclerosis disability and predict progression using routinely collected healthcare data.
   Mult Scler. 2025 Jul 3:13524585251347513. doi: 10.1177/13524585251347513.
   PubMed     Abstract available
   
   
   June 2025
5. CRUZ RIVERA S, Buxhoeveden S, Aiyegbusi OL, Bozinov N, et al
   The importance of patient-reported outcomes: A call for their integration in the routine care of patients with multiple sclerosis.
   Mult Scler. 2025 Jun 29:13524585251349354. doi: 10.1177/13524585251349354.
   PubMed     Abstract available
   
   
   
6. BALSHI A, Dempsey JP, Manning N, Leuenberger G, et al
   Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.
   Mult Scler. 2025 Jun 25:13524585251342725. doi: 10.1177/13524585251342725.
   PubMed     Abstract available
   
   
   
7. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
   Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis.
   Mult Scler. 2025 Jun 19:13524585251345317. doi: 10.1177/13524585251345317.
   PubMed     Abstract available
   
   
   
8. ARAB BAFRANI M, Rios V, Kim MJ, Balan A, et al
   Gynecological health: A missing link in comprehensive treatment monitoring for multiple sclerosis.
   Mult Scler. 2025 Jun 18:13524585251346371. doi: 10.1177/13524585251346371.
   PubMed     Abstract available
   
   
   
9. SAHU M, Chomba M, Mortel D, Braun S, et al
   Factors associated with delay to diagnosis of multiple sclerosis in Zambia.
   Mult Scler. 2025 Jun 17:13524585251344832. doi: 10.1177/13524585251344832.
   PubMed     Abstract available
   
   
   
10. BEREK K, Schmidauer M, Bsteh G, Auer M, et al
    Kappa free light chain index predicts long-term disease activity and disability accrual in multiple sclerosis.
    Mult Scler. 2025 Jun 16:13524585251344807. doi: 10.1177/13524585251344807.
    PubMed     Abstract available
    
    
    
11. STEIN C, O'Keeffe F, Brosnan M, Flynn C, et al
    Cognitive reserve in multiple sclerosis: The role of depression and fatigue.
    Mult Scler. 2025 Jun 11:13524585251338757. doi: 10.1177/13524585251338757.
    PubMed     Abstract available
    
    
    
12. MOCCIA M
    Clinical commentary to gender-affirming interventions and prognosis in multiple sclerosis.
    Mult Scler. 2025 Jun 3:13524585251341177. doi: 10.1177/13524585251341177.
    PubMed    
    
    
    
13. NEYAL N, Nathoo N, Cathcart-Rake EJ, Kantarci OH, et al
    Gender-affirming interventions and prognosis in multiple sclerosis.
    Mult Scler. 2025 Jun 3:13524585251341174. doi: 10.1177/13524585251341174.
    PubMed     Abstract available
    
    
    
14. VARLEY J, Beyrouti R, Nicholas R, Dorsey R, et al
    A comparison of JC virus assay performance provided with originator and biosimilar natalizumab.
    Mult Scler. 2025;31:882-885.
    PubMed     Abstract available
    
    
    
15. VUKUSIC S, Hubben F, Gavoille A, Malek Y, et al
    Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?
    Mult Scler. 2025;31:877-881.
    PubMed     Abstract available
    
    
    
16. GARTHOF S, Schafer S, Elmers J, Schwed L, et al
    Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.
    Mult Scler. 2025;31:856-865.
    PubMed     Abstract available
    
    
    
17. LEAVITT VM, Fox R, Mostert J, D'Haeseleer M, et al
    Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study.
    Mult Scler. 2025;31:866-876.
    PubMed     Abstract available
    
    
    
18. ARNOLD DL, Kolind S, Assemlal HE, Bar-Or A, et al
    Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.
    Mult Scler. 2025;31:821-832.
    PubMed     Abstract available
    
    
    May 2025
19. NOVAKOVA L, Rosenstein I, Axelsson M, Schoonheim MM, et al
    Plateau of practice effects and noise with repeat SDMT testing and in multiple sclerosis.
    Mult Scler. 2025 May 31:13524585251344794. doi: 10.1177/13524585251344794.
    PubMed     Abstract available
    
    
    
20. VILASECA A, Vidal-Jordana A, Sceppacuercia S, Calderon W, et al
    Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?
    Mult Scler. 2025 May 30:13524585251332115. doi: 10.1177/13524585251332115.
    PubMed     Abstract available
    
    
    
21. FOONG YC, Butzkueven H
    Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? - No.
    Mult Scler. 2025 May 26:13524585251344805. doi: 10.1177/13524585251344805.
    PubMed    
    
    
    
22. ROD BE, Hogestol EA, Torkildsen O, Bjornevik K, et al
    Comparative effectiveness of rituximab and cladribine in relapsing-remitting multiple sclerosis: A target trial emulation.
    Mult Scler. 2025 May 26:13524585251342727. doi: 10.1177/13524585251342727.
    PubMed     Abstract available
    
    
    
23. ROSTON S, Quick MH, Tisavipat N, Rattanathamsakul N, et al
    Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.
    Mult Scler. 2025 May 26:13524585251340841. doi: 10.1177/13524585251340841.
    PubMed     Abstract available
    
    
    
24. ZANE GK, Sutton A, Brumwell A, Hossain MR, et al
    The path to prevention of multiple sclerosis: Considerations for Epstein-Barr virus vaccine-based prevention studies.
    Mult Scler. 2025 May 26:13524585251340812. doi: 10.1177/13524585251340812.
    PubMed     Abstract available
    
    
    
25. MARRIE RA, Maxwell CJ, Everett K, Zhu F, et al
    Health care use preceding pediatric multiple sclerosis: A population-based study from Ontario, Canada.
    Mult Scler. 2025 May 23:13524585251338745. doi: 10.1177/13524585251338745.
    PubMed     Abstract available
    
    
    
26. MACCARRONE D, Prados F, Ciccarelli O
    The relationship between cladribine and reduced regional grey matter volume loss in people with relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 May 3:13524585251338772. doi: 10.1177/13524585251338772.
    PubMed    
    
    
    
27. LOREFICE L, Zivadinov R
    Treating comorbidities in multiple sclerosis is disease-modifying: Yes.
    Mult Scler. 2025 May 3:13524585251338750. doi: 10.1177/13524585251338750.
    PubMed    
    
    
    
28. GRESELIN M, Lu PJ, Mroczek M, Cerda-Fuertes N, et al
    AI-assisted identification of disability patterns within identical EDSS grades.
    Mult Scler. 2025;31:677-688.
    PubMed     Abstract available
    
    
    
29. FOX RJ, Cohan S, Mao-Draayer Y, Weinstock-Guttman B, et al
    Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study.
    Mult Scler. 2025;31:706-718.
    PubMed     Abstract available
    
    
    
30. LEE A, Iordanova RT, Smith JB, Li BH, et al
    Incidence and prevalence of neuromyelitis optica spectrum disorder in a contemporary, multi-ethnic cohort.
    Mult Scler. 2025;31:642-657.
    PubMed     Abstract available
    
    
    
31. CHAN F, Berhanu D, Samadzadeh S, Francis A, et al
    Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD.
    Mult Scler. 2025;31:658-667.
    PubMed     Abstract available
    
    
    April 2025
32. YALDIZLI O, Benkert P, Achtnichts L, Bar-Or A, et al
    Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.
    Mult Scler. 2025 Apr 28:13524585251335466. doi: 10.1177/13524585251335466.
    PubMed     Abstract available
    
    
    
33. STEPHENS S, Iseyas N, Yeh EA
    Physical activity demonstrates protective associations with structural visual metrics in children with multiple sclerosis through time.
    Mult Scler. 2025 Apr 28:13524585251335510. doi: 10.1177/13524585251335510.
    PubMed     Abstract available
    
    
    
34. PILOTTO S, Pontieri L, Nielsen HH, Rasmussen PV, et al
    Pediatric Onset Multiple Sclerosis (POMS): Exploring phenotypic characterization and pubertal influences in modulating the disease activity from the Danish MS Registry (DMSR).
    Mult Scler. 2025 Apr 28:13524585251335476. doi: 10.1177/13524585251335476.
    PubMed     Abstract available
    
    
    
35. MADILL E, Moreira Ferreira V, Healy B, Zurawski J, et al
    Change in serum neurofilament light chain and glial fibrillary acidic protein levels with high-efficacy and low-efficacy early therapy in multiple sclerosis.
    Mult Scler. 2025 Apr 28:13524585251335521. doi: 10.1177/13524585251335521.
    PubMed     Abstract available
    
    
    
36. FERRAZZANO G, Maccarrone D, Guerra A, Collura A, et al
    The effects of gamma-tACS on cognitive impairment in multiple sclerosis: A randomized, double-blind, sham-controlled, pilot study.
    Mult Scler. 2025 Apr 26:13524585251333575. doi: 10.1177/13524585251333575.
    PubMed     Abstract available
    
    
    
37. GREENWALD MA, Cancel Asencio HG, Dwyer J, Moss A, et al
    Differential Validity in the Written, Oral, and Electronic SDMT in Multiple Sclerosis.
    Mult Scler. 2025 Apr 24:13524585251330961. doi: 10.1177/13524585251330961.
    PubMed     Abstract available
    
    
    
38. KRAJNC N, Fottinger F, Ponleitner M, Kornek B, et al
    Diagnostic accuracy of inter-eye difference of ganglion cell layer alone in identifying optic neuritis in multiple sclerosis.
    Mult Scler. 2025 Apr 22:13524585251332895. doi: 10.1177/13524585251332895.
    PubMed     Abstract available
    
    
    
39. MARRIE RA, Bolton JM, Ling V, Bernstein CN, et al
    Risk factors for incident peripartum mental illness in multiple sclerosis.
    Mult Scler. 2025 Apr 18:13524585251330109. doi: 10.1177/13524585251330109.
    PubMed     Abstract available
    
    
    
40. MACARON G, Farah N, Charbonneau S, Morrow SA, et al
    Addressing patient-reported cognitive impairment in multiple sclerosis clinical practice: A challenging endeavor.
    Mult Scler. 2025 Apr 18:13524585251334488. doi: 10.1177/13524585251334488.
    PubMed     Abstract available
    
    
    
41. FADLALLAH Y, Wang Y, Malik MT, Tian F, et al
    Frequency and potential risk factors associated with the development of asymptomatic T2 hyperintense cervical spine lesions on MRI in patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 Apr 17:13524585251331405. doi: 10.1177/13524585251331405.
    PubMed     Abstract available
    
    
    
42. JENSEN MP, Robles S, Nash MG, May S, et al
    Hypnosis and mindfulness audio recordings for reducing fatigue in individuals with multiple sclerosis: A randomized controlled study.
    Mult Scler. 2025 Apr 17:13524585251329820. doi: 10.1177/13524585251329820.
    PubMed     Abstract available
    
    
    
43. EL AYOUBI NK, Bal MN, Metri N, El Sammak S, et al
    Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study.
    Mult Scler. 2025 Apr 12:13524585251332499. doi: 10.1177/13524585251332499.
    PubMed     Abstract available
    
    
    
44. BSTEH G, Hegen H, Albrecht P, Havla J, et al
    Emphasizing complementary in "Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis".
    Mult Scler. 2025 Apr 12:13524585251329800. doi: 10.1177/13524585251329800.
    PubMed    
    
    
    
45. CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
    Response to letter to the editor: 'Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis'.
    Mult Scler. 2025 Apr 12:13524585251329787. doi: 10.1177/13524585251329787.
    PubMed    
    
    
    
46. LIU X, Wang Y, Wei N, Zhu W, et al
    The characteristics and influencing factors of paramagnetic rim lesions in Chinese MS patients: A 7T MRI study.
    Mult Scler. 2025 Apr 12:13524585251328902. doi: 10.1177/13524585251328902.
    PubMed     Abstract available
    
    
    
47. REVIE L, Jurjens A, Eveslage M, Trumpelmann S, et al
    Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab.
    Mult Scler. 2025 Apr 3:13524585251329849. doi: 10.1177/13524585251329849.
    PubMed     Abstract available
    
    
    
48. SAYLOR D, Rijke N, McDonell J, Laurson-Doube J, et al
    Recommendations for essential medicines for multiple sclerosis in low-resource settings.
    Mult Scler. 2025;31:464-473.
    PubMed     Abstract available
    
    
    
49. BARANZINI SE
    The Barancik award lecture: Multi-disciplinary research will be the key to stop, restore, and end MS.
    Mult Scler. 2025;31:384-391.
    PubMed     Abstract available
    
    
    
50. MERLO D, Ja J, Foong YC, Zhu C, et al
    Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis.
    Mult Scler. 2025 Apr 1:13524585251329035. doi: 10.1177/13524585251329035.
    PubMed     Abstract available
    
    
    
51. BOBELNA B, Lobjois Q, Croitoru S, Jalkh E, et al
    Incidence of optic neuritis among Afro-descendant, a cohort study.
    Mult Scler. 2025;31:529-538.
    PubMed     Abstract available
    
    
    
52. BUDHRAM A, Flanagan EP
    Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how.
    Mult Scler. 2025;31:505-511.
    PubMed     Abstract available
    
    
    
53. SONI RH, Garcia M, Oak E, Applbaum EJ, et al
    Acute eculizumab treatment in a pediatric patient with AQP4-IgG+ NMOSD.
    Mult Scler. 2025;31:612-614.
    PubMed     Abstract available
    
    
    
54. TOMMASO G, Damiano P, Pietro I
    Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report.
    Mult Scler. 2025;31:615-617.
    PubMed     Abstract available
    
    
    
55. LAAKSO SM, Oh J, Raufdeen F, Jones A, et al
    Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort.
    Mult Scler. 2025;31:607-611.
    PubMed     Abstract available
    
    
    March 2025
56. CIAMPI E, Garcia L, Carcamo C, Soler B, et al
    Practical issues concerning the use of optical coherence tomography in multiple sclerosis in Latin America: Discussion from 19 centres on behalf of the Foro Latam EM study group.
    Mult Scler. 2025 Mar 29:13524585251329159. doi: 10.1177/13524585251329159.
    PubMed     Abstract available
    
    
    
57. LEVIT E, Cohen I, Mahajan A, Ulano A, et al
    Evaluation of the relationship between brainstem lesions and apnea hypopnea index in patients with multiple sclerosis.
    Mult Scler. 2025 Mar 29:13524585251327875. doi: 10.1177/13524585251327875.
    PubMed     Abstract available
    
    
    
58. NOROOZI R, Tsai HH, Yu K, Bronson P, et al
    Metabolic and lipid alterations in multiple sclerosis linked to disease severity.
    Mult Scler. 2025 Mar 27:13524585251325468. doi: 10.1177/13524585251325468.
    PubMed     Abstract available
    
    
    
59. LIU X, Zhang C
    Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
    Mult Scler. 2025 Mar 27:13524585251324854. doi: 10.1177/13524585251324854.
    PubMed    
    
    
    
60. SIMANI L, Leavitt VM
    Response to the letter: Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
    Mult Scler. 2025 Mar 27:13524585251324872. doi: 10.1177/13524585251324872.
    PubMed    
    
    
    
61. BAKIRTZIS C, Dimitriou N, Moysiadis T, El-Wahsh S, et al
    Communication deficits in multiple sclerosis: Interactions with cognitive dysfunction and their impact on employment status.
    Mult Scler. 2025 Mar 20:13524585251328556. doi: 10.1177/13524585251328556.
    PubMed     Abstract available
    
    
    
62. FREEDMAN DE, Oh J, Meza C, Feinstein A, et al
    Seizure history and cognitive dysfunction in people with multiple sclerosis.
    Mult Scler. 2025 Mar 18:13524585251326841. doi: 10.1177/13524585251326841.
    PubMed     Abstract available
    
    
    
63. WILLIAMS J, Marin WM, Wade KJ, Suseno R, et al
    Copy number variation at the complement C4 locus is associated with risk for multiple sclerosis.
    Mult Scler. 2025 Mar 15:13524585251324850. doi: 10.1177/13524585251324850.
    PubMed     Abstract available
    
    
    
64. CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al
    Short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis.
    Mult Scler. 2025 Mar 13:13524585251323178. doi: 10.1177/13524585251323178.
    PubMed     Abstract available
    
    
    
65. CARVAJAL R, Tur C, Borras-Bermejo B, Saylor D, et al
    Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization.
    Mult Scler. 2025 Mar 12:13524585251318513. doi: 10.1177/13524585251318513.
    PubMed     Abstract available
    
    
    
66. MAILLART E, Rollot F, Leray E, Benyahya L, et al
    Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population.
    Mult Scler. 2025;31:324-337.
    PubMed     Abstract available
    
    
    
67. ZEYDAN B, Son J, Neyal N, Schwarz CG, et al
    Upper cervical spinal cord atrophy in MS: Sex, menopause, and neurodegeneration.
    Mult Scler. 2025;31:278-289.
    PubMed     Abstract available
    
    
    
68. LEBRUN-FRENAY C
    The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives.
    Mult Scler. 2025;31:249-256.
    PubMed     Abstract available
    
    
    
69. AL GBURI M, Mazzola M, Absinta M, Gaitan MI, et al
    Paramagnetic rim lesion formation is predicted by the initial gadolinium-enhancing lesion diameter.
    Mult Scler. 2025;31:263-277.
    PubMed     Abstract available
    
    
    
70. RAMDANI R, Pique J, Deschamps R, Ciron J, et al
    Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study.
    Mult Scler. 2025;31:290-302.
    PubMed     Abstract available
    
    
    February 2025
71. STOGBAUER J, Schegerer V, Berger FK, Schulz-Schaeffer W, et al
    Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a young woman under long-term B-cell depletion with ocrelizumab: A case report.
    Mult Scler. 2025 Feb 27:13524585251322327. doi: 10.1177/13524585251322327.
    PubMed     Abstract available
    
    
    
72. BALSHI A
    Climate change and multiple sclerosis: Clinical challenges and strategies.
    Mult Scler. 2025 Feb 26:13524585251322664. doi: 10.1177/13524585251322664.
    PubMed     Abstract available
    
    
    
73. GOGA JJ, Ginell KM, Ng YT, Ehde DM, et al
    Feasibility, reliability, and validity of ambulatory smartphone-administered cognitive tests in multiple sclerosis.
    Mult Scler. 2025 Feb 25:13524585251320814. doi: 10.1177/13524585251320814.
    PubMed     Abstract available
    
    
    
74. BARRANTES-CEPAS M, Noteboom S, Colato E, Battaglini M, et al
    Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.
    Mult Scler. 2025 Feb 25:13524585251314779. doi: 10.1177/13524585251314779.
    PubMed     Abstract available
    
    
    
75. DELUCA J
    An interdisciplinary approach is necessary in the treatment of cognitive decline in Multiple Sclerosis: Commentary.
    Mult Scler. 2025 Feb 25:13524585251315357. doi: 10.1177/13524585251315357.
    PubMed    
    
    
    
76. DONKERS SJ, Walker LA
    An interdisciplinary approach is necessary in the treatment of cognitive decline in multiple sclerosis - YES.
    Mult Scler. 2025 Feb 25:13524585251315344. doi: 10.1177/13524585251315344.
    PubMed    
    
    
    
77. SCHOEPS VA, Smith JB, Langer-Gould A
    Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibility.
    Mult Scler. 2025 Feb 19:13524585251318293. doi: 10.1177/13524585251318293.
    PubMed     Abstract available
    
    
    
78. LINDBERG S, Sandgren S, Axelsson M, Rosenstein I, et al
    Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.
    Mult Scler. 2025 Feb 18:13524585251318516. doi: 10.1177/13524585251318516.
    PubMed     Abstract available
    
    
    
79. KARATSIDIS A, Angelini L, Scaramozza M, Bartholome E, et al
    Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework.
    Mult Scler. 2025 Feb 18:13524585251316242. doi: 10.1177/13524585251316242.
    PubMed     Abstract available
    
    
    
80. MITRACHE DESAGA AC, Noui Y, Silfverberg T, Carlson K, et al
    Patient-reported outcomes of quality of life before and after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2025 Feb 17:13524585251315363. doi: 10.1177/13524585251315363.
    PubMed     Abstract available
    
    
    
81. SIMONSEN CS, Flemmen HO, Broch L, Brekke K, et al
    Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study.
    Mult Scler. 2025 Feb 17:13524585251315077. doi: 10.1177/13524585251315077.
    PubMed     Abstract available
    
    
    
82. VAVASOUR I, Elliott C, Arnold DL, Gaetano L, et al
    Presence of slowly expanding lesions in multiple sclerosis predicts progressive demyelination within lesions and normal-appearing tissue over time.
    Mult Scler. 2025 Feb 14:13524585251316519. doi: 10.1177/13524585251316519.
    PubMed     Abstract available
    
    
    
83. ALBERGONI M, Preziosa P, Meani A, Dallari C, et al
    Aerobic capacity moderates the association between cervical cord atrophy and clinical disability in mildly disabled multiple sclerosis patients.
    Mult Scler. 2025 Feb 14:13524585251318647. doi: 10.1177/13524585251318647.
    PubMed     Abstract available
    
    
    
84. MARRODAN M, Sao Aviles A, Rio J, Cobo-Calvo A, et al
    Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.
    Mult Scler. 2025 Feb 10:13524585251316471. doi: 10.1177/13524585251316471.
    PubMed     Abstract available
    
    
    
85. VILASECA A, Tintore M, Carbonell-Mirabent P, Rodriguez-Barranco M, et al
    Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort.
    Mult Scler. 2025 Feb 5:13524585251314749. doi: 10.1177/13524585251314749.
    PubMed     Abstract available
    
    
    
86. SUMOWSKI JF, Sandry J
    Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty.
    Mult Scler. 2025 Feb 2:13524585241309805. doi: 10.1177/13524585241309805.
    PubMed     Abstract available
    
    
    
87. TAUL-MADSEN L, Hvid LG, Riis H, Brolos MK, et al
    A head-to-head comparison of the effects of aerobic versus resistance training on physical capacity and physical function in people with multiple sclerosis: Results from the MSBOOST trial.
    Mult Scler. 2025;31:174-183.
    PubMed     Abstract available
    
    
    
88. CACCIAGUERRA L, Storelli L, Pagani E, Preziosa P, et al
    Use of brain MRI and gene expression atlases to reconstruct the pathophysiology of autoimmune neurological disorders: The proof-of-concept of NMOSD.
    Mult Scler. 2025;31:140-158.
    PubMed     Abstract available
    
    
    
89. CORBOY JR, Fox RJ, Cutter G, Engebretson E, et al
    DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
    Mult Scler. 2025;31:159-173.
    PubMed     Abstract available
    
    
    
90. LEBRUN-FRENAY C, Kerbrat S, Okuda DT, Landes-Chateau C, et al
    Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome.
    Mult Scler. 2025;31:184-196.
    PubMed     Abstract available
    
    
    
91. PATEL AD, Connors A, Esch ME
    Ofatumumab-associated colitis: A case report.
    Mult Scler. 2025;31:242-245.
    PubMed     Abstract available
    
    
    January 2025
92. MARTIRE MS, Moiola L, Maggi P, Borrelli S, et al
    Reliability of paramagnetic rim lesion detection at 1.5T MRI in multiple sclerosis patients.
    Mult Scler. 2025 Jan 31:13524585251314358. doi: 10.1177/13524585251314358.
    PubMed     Abstract available
    
    
    
93. ACHIRON A, Warszawer Y, Nissan Y, Kerpel A, et al
    Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study.
    Mult Scler. 2025 Jan 27:13524585251313749. doi: 10.1177/13524585251313749.
    PubMed     Abstract available
    
    
    
94. DE ANGELIS F, Ammoscato F, Parker RA, Plantone D, et al
    Neurofilament heavy chain in secondary progressive multiple sclerosis.
    Mult Scler. 2025 Jan 22:13524585241311212. doi: 10.1177/13524585241311212.
    PubMed     Abstract available
    
    
    
95. VARLEY JA, Davies NW
    Opportunistic enteroviral infections in MS patients treated with anti-CD20 therapies.
    Mult Scler. 2025 Jan 20:13524585241310395. doi: 10.1177/13524585241310395.
    PubMed    
    
    
    
96. YILMAZER C, D'haeseleer M, Soler B, Van Wijmeersch B, et al
    Assessing pain in multiple sclerosis: Test-retest reliability of patient-reported outcome measures and accuracy of screening tools.
    Mult Scler. 2025 Jan 16:13524585241310139. doi: 10.1177/13524585241310139.
    PubMed     Abstract available
    
    
    
97. DEL CANTO A, Carcamo C, Garcia L, Aylwin E, et al
    Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis.
    Mult Scler. 2025 Jan 6:13524585241309835. doi: 10.1177/13524585241309835.
    PubMed     Abstract available
    
    
    
98. WITT L, Dost-Kovalsky K, Friedmann N, Bast N, et al
    Ofatumumab-exposed breastfeeding in multiple sclerosis patients.
    Mult Scler. 2025 Jan 6:13524585241307165. doi: 10.1177/13524585241307165.
    PubMed     Abstract available
    
    
    
99. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
    Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis.
    Mult Scler. 2025 Jan 3:13524585241310104. doi: 10.1177/13524585241310104.
    PubMed     Abstract available
    
    
    
100. SIMANI L, Tozlu C, Lee S, Dworkin J, et al
     Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
     Mult Scler. 2025 Jan 3:13524585241303491. doi: 10.1177/13524585241303491.
     PubMed     Abstract available
     
     
     
101. GIOVANNONI G, Boyko A, Correale J, Edan G, et al
     Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
     Mult Scler. 2025;31:44-58.
     PubMed     Abstract available
     
     
     
102. MANISCALCO GT, Dinoto A, Foglia MC, Di Battista ME, et al
     Epstein-Barr virus infection in patients with MOGAD.
     Mult Scler. 2025;31:117-120.
     PubMed     Abstract available
     
     
     
103. CARNERO CONTENTTI E, Rotstein D, Okuda DT, Paul F, et al
     How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder.
     Mult Scler. 2025;31:8-22.
     PubMed     Abstract available
     
     
     December 2024
104. MAGGI G, Altieri M, Risi M, Rippa V, et al
     Cognitive reserve predicts long-term cognitive trajectories in relapsing-remitting multiple sclerosis.
     Mult Scler. 2024 Dec 27:13524585241302167. doi: 10.1177/13524585241302167.
     PubMed     Abstract available
     
     
     
105. BRIGGS FB, Conway DS, Hersh CM, Fitzgerald KC, et al
     The onset presentation of multiple sclerosis differs in Hispanic/Latinx Americans compared with non-Hispanic White Americans.
     Mult Scler. 2024 Dec 24:13524585241304976. doi: 10.1177/13524585241304976.
     PubMed     Abstract available
     
     
     
106. CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
     Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis.
     Mult Scler. 2024 Dec 20:13524585241304356. doi: 10.1177/13524585241304356.
     PubMed     Abstract available
     
     
     
107. MALLUCCI G, Zimmer A, Sfikas N, Cerda-Fuertes N, et al
     Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.
     Mult Scler. 2024 Dec 20:13524585241305966. doi: 10.1177/13524585241305966.
     PubMed     Abstract available
     
     
     
108. CORREALE J, Marrodan M
     Live-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: A complex decision.
     Mult Scler. 2024 Dec 18:13524585241305956. doi: 10.1177/13524585241305956.
     PubMed     Abstract available
     
     
     
109. NYLANDER A, Sisodia N, Henderson K, Wijangco J, et al
     From "invisible" to "audible": Features extracted during simple speech tasks classify patient-reported fatigue in multiple sclerosis.
     Mult Scler. 2024 Dec 17:13524585241303855. doi: 10.1177/13524585241303855.
     PubMed     Abstract available
     
     
     
110. VAN DAM M, Rottgering JG, Nauta IM, de Jong BA, et al
     Understanding the complex network of objectively assessed cognition and self-reported psychological symptoms in people with multiple sclerosis.
     Mult Scler. 2024 Dec 9:13524585241302173. doi: 10.1177/13524585241302173.
     PubMed     Abstract available
     
     
     
111. KRYSKO KM
     Considerations for family planning in adolescent and young adults with multiple sclerosis.
     Mult Scler. 2024 Dec 7:13524585241303481. doi: 10.1177/13524585241303481.
     PubMed    
     
     
     
112. CHANG G, Stoney S, Narula S
     Pregnancy outcomes in adolescent and young adult patients with multiple sclerosis: A case series.
     Mult Scler. 2024 Dec 7:13524585241303490. doi: 10.1177/13524585241303490.
     PubMed     Abstract available
     
     
     
113. FRAMKE E, Sellebjerg F, Kant M, Stilund M, et al
     Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.
     Mult Scler. 2024 Dec 4:13524585241299715. doi: 10.1177/13524585241299715.
     PubMed     Abstract available
     
     
     
114. CARVAJAL R, Rodriguez-Acevedo B, Garcia-Vasco L, Zabalza A, et al
     Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies.
     Mult Scler. 2024;30:1788-1801.
     PubMed     Abstract available
     
     
     
115. KEVER A, Heuer LB, Simani L, Leavitt VM, et al
     Development and initial validation of the Cognitive Change Scale (CCS).
     Mult Scler. 2024;30:1815-1824.
     PubMed     Abstract available
     
     
     
116. JIANG X, McGinley M, Johnston J, Alberts J, et al
     A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosis.
     Mult Scler. 2024 Dec 1:13524585241301854. doi: 10.1177/13524585241301854.
     PubMed     Abstract available
     
     
     
117. CHITNIS T, Arnold DL, Quartier P, Chirieac M, et al
     Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study.
     Mult Scler. 2024 Dec 1:13524585241295554. doi: 10.1177/13524585241295554.
     PubMed     Abstract available
     
     
     
118. PORTACCIO E
     Toward a holistic approach to multiple sclerosis: The role of social determinants of health.
     Mult Scler. 2024 Dec 1:13524585241302684. doi: 10.1177/13524585241302684.
     PubMed    
     
     
     
119. LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al
     Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
     Mult Scler. 2024 Dec 1:13524585241289276. doi: 10.1177/13524585241289276.
     PubMed     Abstract available
     
     
     
120. GAITAN MI, Marquez RV, Ayerbe J, Reich DS, et al
     Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
121. MOTL RW
     Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
122. PILUTTI LA, Donkers SJ
     Exercise as a Therapeutic Intervention in Multiple Sclerosis.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
123. MCGINLEY MP
     Improving Access to MS Care Through Technology.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
124. BERGSLAND N, Dwyer MG, Zivadinov R
     Imaging the Choroid Plexus.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
125. LANGER-GOULD A
     Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics: No.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
126. KOCH MW, Camara-Lemarroy C, Strijbis E, Mostert J, et al
     Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
127. ONTANEDA D, Miron VE
     Breaking Barriers in Multiple Sclerosis.
     Mult Scler. 2024;30.
     PubMed    
     
     
     November 2024
128. LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al
     Association between education level and disability progression in patients with multiple sclerosis in France.
     Mult Scler. 2024 Nov 30:13524585241289274. doi: 10.1177/13524585241289274.
     PubMed     Abstract available
     
     
     
129. KALAITZIDIS G, Ezzedin O, Bacchetti A, Moussa H, et al
     Homonymous hemi-macular atrophy in multiple sclerosis.
     Mult Scler. 2024 Nov 23:13524585241297816. doi: 10.1177/13524585241297816.
     PubMed     Abstract available
     
     
     
130. GANS A, Verrengia EP, Ricchiuti E, Leva S, et al
     Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review.
     Mult Scler. 2024 Nov 21:13524585241295677. doi: 10.1177/13524585241295677.
     PubMed     Abstract available
     
     
     
131. DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
     Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study.
     Mult Scler. 2024 Nov 14:13524585241297003. doi: 10.1177/13524585241297003.
     PubMed     Abstract available
     
     
     
132. MAGGI P, Absinta M
     Emerging MRI biomarkers for the diagnosis of multiple sclerosis.
     Mult Scler. 2024 Nov 7:13524585241293579. doi: 10.1177/13524585241293579.
     PubMed     Abstract available
     
     
     
133. HOFFMAN EM, Brown L, Jolliffe E, Sechi E, et al
     McArdle sign and neck flexion-induced change in central motor conduction in multiple sclerosis.
     Mult Scler. 2024 Nov 6:13524585241295868. doi: 10.1177/13524585241295868.
     PubMed     Abstract available
     
     
     
134. WITT L, Haben S, Dost-Kovalsky K, Friedmann N, et al
     Impact of symptomatic multiple sclerosis therapy on pregnancy outcome.
     Mult Scler. 2024 Nov 6:13524585241293363. doi: 10.1177/13524585241293363.
     PubMed     Abstract available
     
     
     
135. HOCHSTETLER A, Lehtinen MK
     Choroid plexus as a mediator of CNS inflammation in multiple sclerosis.
     Mult Scler. 2024 Nov 6:13524585241292974. doi: 10.1177/13524585241292974.
     PubMed     Abstract available
     
     
     
136. JIANG Y, Cesta CE, Liu Q, Kingwell E, et al
     Exploring the relationship between polycystic ovarian syndrome, testosterone, and multiple sclerosis in women: A nationwide cohort study and genome-wide cross-trait analysis.
     Mult Scler. 2024 Nov 6:13524585241292802. doi: 10.1177/13524585241292802.
     PubMed     Abstract available
     
     
     
137. TOOROP AA, Wessels MH, Boonkamp L, Gelissen LM, et al
     Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
     Mult Scler. 2024 Nov 4:13524585241293940. doi: 10.1177/13524585241293940.
     PubMed     Abstract available
     
     
     
138. HSU S, Balan A, Bove R
     Topical review: Lactation and use of DMTs in women with MS.
     Mult Scler. 2024;30:1578-1591.
     PubMed     Abstract available
     
     
     
139. NOVI G, Sbragia E, Benedetti L, Schenone A, et al
     Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder.
     Mult Scler. 2024;30:1692-1696.
     PubMed     Abstract available
     
     
     October 2024
140. YOUNG CA, Rog DJ, Sharrack B, Tanasescu R, et al
     Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple Sclerosis Impact Scale (MSIS-29).
     Mult Scler. 2024 Oct 30:13524585241288393. doi: 10.1177/13524585241288393.
     PubMed     Abstract available
     
     
     
141. TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
     Phenotyping in vivo chronic inflammation in multiple sclerosis by combined (11)C-PBR28 MR-PET and 7T susceptibility-weighted imaging.
     Mult Scler. 2024 Oct 22:13524585241284157. doi: 10.1177/13524585241284157.
     PubMed     Abstract available
     
     
     
142. 
     Erratum to "Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis" Multiple Sclerosis Journal; 2024: 30(8); 1086-1088. DOI: 10.1177/13524585241260564.
     Mult Scler. 2024 Oct 22:13524585241290986. doi: 10.1177/13524585241290986.
     PubMed    
     
     
     
143. PALLADINO R, Chataway J, Mathew M, Majeed A, et al
     Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.
     Mult Scler. 2024 Oct 17:13524585241287388. doi: 10.1177/13524585241287388.
     PubMed     Abstract available
     
     
     
144. DE NADAI AS, Zamora RJ, Finch A, Miller DM, et al
     Multiple sclerosis subgroups: Data-driven clusters based on patient-reported outcomes and a large clinical sample.
     Mult Scler. 2024 Oct 17:13524585241282763. doi: 10.1177/13524585241282763.
     PubMed     Abstract available
     
     
     
145. VAN LIEROP ZY, Wessels MH, Lekranty WM, Moraal B, et al
     Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.
     Mult Scler. 2024 Oct 17:13524585241277044. doi: 10.1177/13524585241277044.
     PubMed     Abstract available
     
     
     
146. VLAD B, Neidhart S, Hilty M, Asplund Hogelin K, et al
     Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis.
     Mult Scler. 2024 Oct 8:13524585241279645. doi: 10.1177/13524585241279645.
     PubMed     Abstract available
     
     
     
147. AMEZCUA L, Hamilton RH, Ciccarelli O
     The current state of diversity, equity, and inclusion in multiple sclerosis research, clinical trials, and workforce.
     Mult Scler. 2024 Oct 8:13524585241286988. doi: 10.1177/13524585241286988.
     PubMed    
     
     
     
148. VERCELLINO M, Marasciulo S, Ricotti E, Rolando A, et al
     Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis.
     Mult Scler. 2024 Oct 7:13524585241284846. doi: 10.1177/13524585241284846.
     PubMed     Abstract available
     
     
     
149. LEE S, Marrie RA, Fadda G, Freedman MS, et al
     Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     September 2024
150. NESBITT C, Van Der Walt A, Butzkueven H, Devitt B, et al
     Multiple sclerosis and cancer: Navigating a dual diagnosis.
     Mult Scler. 2024 Sep 30:13524585241274523. doi: 10.1177/13524585241274523.
     PubMed     Abstract available
     
     
     
151. BAYOUMI A, Hasan KM, Thomas JA, Yazdani A, et al
     Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability.
     Mult Scler. 2024 Sep 29:13524585241280842. doi: 10.1177/13524585241280842.
     PubMed     Abstract available
     
     
     
152. OCAMPO A, Hatami F, Cuklina J, Graham G, et al
     Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.
     Mult Scler. 2024 Sep 28:13524585241275471. doi: 10.1177/13524585241275471.
     PubMed     Abstract available
     
     
     
153. INOJOSA H, Voigt I, Wenk J, Ferber D, et al
     Integrating large language models in care, research, and education in multiple sclerosis management.
     Mult Scler. 2024 Sep 23:13524585241277376. doi: 10.1177/13524585241277376.
     PubMed     Abstract available
     
     
     
154. JACOBS BM, Schalk L, Tregaskis-Daniels E, Tank P, et al
     The relationship between ethnicity and multiple sclerosis characteristics in the United Kingdom: A UK MS Register study.
     Mult Scler. 2024 Sep 20:13524585241277018. doi: 10.1177/13524585241277018.
     PubMed     Abstract available
     
     
     
155. O'DONNELL E, Schuette A, Waltz M, Aaen G, et al
     Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis.
     Mult Scler. 2024 Sep 17:13524585241274580. doi: 10.1177/13524585241274580.
     PubMed     Abstract available
     
     
     
156. PILLONI G, Lustberg M, Malik M, Feinberg C, et al
     Hand functioning in progressive multiple sclerosis improves with tDCS added to daily exercises: A home-based randomized, double-blinded, sham-controlled clinical trial.
     Mult Scler. 2024 Sep 13:13524585241275013. doi: 10.1177/13524585241275013.
     PubMed     Abstract available
     
     
     
157. LANDI D, Bartolomeo S, Bovis F, Amato MP, et al
     Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy.
     Mult Scler. 2024 Sep 12:13524585241274600. doi: 10.1177/13524585241274600.
     PubMed     Abstract available
     
     
     
158. HOLTZER R, Foley FW, Motl RW, Wagshul ME, et al
     Brain hemodynamic responses and fall prediction in older adults with multiple sclerosis.
     Mult Scler. 2024 Sep 11:13524585241277400. doi: 10.1177/13524585241277400.
     PubMed     Abstract available
     
     
     
159. PIEDRABUENA MA, Correale J, Farez MF, Rodriguez Murua S, et al
     Telomere length as a biomarker in multiple sclerosis.
     Mult Scler. 2024 Sep 9:13524585241273054. doi: 10.1177/13524585241273054.
     PubMed     Abstract available
     
     
     
160. LUNEMANN JD, Sao Aviles A, Tintore M, Midaglia L, et al
     Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset.
     Mult Scler. 2024 Sep 9:13524585241274571. doi: 10.1177/13524585241274571.
     PubMed     Abstract available
     
     
     
161. ZURRER WE, Cannon AE, Ilchenko D, Gaitan MI, et al
     Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis.
     Mult Scler. 2024 Sep 8:13524585241274527. doi: 10.1177/13524585241274527.
     PubMed     Abstract available
     
     
     
162. SARTHOU A, Chretien P, Giorgi L, Chiron A, et al
     The kappa free light chains index is an accurate diagnostic biomarker for paediatric multiple sclerosis.
     Mult Scler. 2024 Sep 8:13524585241274034. doi: 10.1177/13524585241274034.
     PubMed     Abstract available
     
     
     
163. COERVER EM, Kacar S, Ciccarelli O, Sormani MP, et al
     Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.
     Mult Scler. 2024 Sep 8:13524585241272938. doi: 10.1177/13524585241272938.
     PubMed     Abstract available
     
     
     
164. BRIGGS FB, Gunzler DD, Miller DM, Ontaneda D, et al
     Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot walk and a patient-reported outcome measure.
     Mult Scler. 2024 Sep 5:13524585241274607. doi: 10.1177/13524585241274607.
     PubMed     Abstract available
     
     
     
165. PETRACCA M, Ruggieri S, Nistri R, Tomasso I, et al
     Brain reserve and timing of clinical onset in multiple sclerosis.
     Mult Scler. 2024 Sep 5:13524585241272046. doi: 10.1177/13524585241272046.
     PubMed     Abstract available
     
     
     
166. TOLJAN K, Daboul L, Raza P, Martin ML, et al
     Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis.
     Mult Scler. 2024 Sep 5:13524585241271988. doi: 10.1177/13524585241271988.
     PubMed     Abstract available
     
     
     
167. LANDES-CHATEAU C, Ricigliano VA, Mondot L, Thouvenot E, et al
     Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome.
     Mult Scler. 2024;30:1278-1289.
     PubMed     Abstract available
     
     
     
168. CHICO-GARCIA JL, Sainz Amo R, Monreal E, Sainz de la Maza S, et al
     Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study.
     Mult Scler. 2024;30:1341-1349.
     PubMed     Abstract available
     
     
     
169. ROTSTEIN DL, Freedman MS, Konig A, Lee L, et al
     Investigation of health care use and a possible prodrome before the first attack in NMOSD and MOGAD.
     Mult Scler. 2024;30:1331-1340.
     PubMed     Abstract available
     
     
     
170. COBO-CALVO A, Tintore M
     Prioritizing global strategies to cure MS.
     Mult Scler. 2024;30:1239-1241.
     PubMed    
     
     
     
171. ABBATEMARCO JR, Aboseif A, Swetlik C, Widmar J, et al
     Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorder.
     Mult Scler. 2024;30:1322-1330.
     PubMed     Abstract available
     
     
     
172. KRUPP L, O'Neill KA
     Monitoring cognitive functioning in MS will trigger anxiety in patients: Yes.
     Mult Scler. 2024;30:1252-1254.
     PubMed    
     
     
     
173. KLEIN M
     Monitoring cognitive functioning in MS will trigger anxiety in patients: No.
     Mult Scler. 2024;30:1254-1256.
     PubMed    
     
     
     August 2024
174. BEBO BF JR, Banwell BL, Whitacre CC, Coetzee T, et al
     The refined Pathways to Cures Research Roadmap for multiple sclerosis cures.
     Mult Scler. 2024 Aug 30:13524585241266483. doi: 10.1177/13524585241266483.
     PubMed     Abstract available
     
     
     
175. ZICCARDI S, Guandalini M, Fuchs TA, Calabrese M, et al
     The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now.
     Mult Scler. 2024 Aug 28:13524585241264476. doi: 10.1177/13524585241264476.
     PubMed     Abstract available
     
     
     
176. FUCHS TA, Schoonheim MM, Zivadinov R, Dwyer MG, et al
     Cognitive progression independent of relapse in multiple sclerosis.
     Mult Scler. 2024 Aug 28:13524585241256540. doi: 10.1177/13524585241256540.
     PubMed     Abstract available
     
     
     
177. TUR C, Portaccio E
     Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline.
     Mult Scler. 2024 Aug 28:13524585241273037. doi: 10.1177/13524585241273037.
     PubMed    
     
     
     
178. RIVERO-DE-AGUILAR A, Perez-Rios M, Mascarenas-Garcia M, Ruano-Ravina A, et al
     Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals.
     Mult Scler. 2024 Aug 27:13524585241273089. doi: 10.1177/13524585241273089.
     PubMed     Abstract available
     
     
     
179. CICCARESE G, Zanghi A, Herzum A, Fidanzi C, et al
     Acute urticaria following ofatumumab injection for multiple sclerosis.
     Mult Scler. 2024 Aug 26:13524585241273084. doi: 10.1177/13524585241273084.
     PubMed    
     
     
     
180. HARROUD A, Sawcer SJ, Baranzini SE
     Genetics of multiple sclerosis severity: The importance of statistical power in replication studies.
     Mult Scler. 2024 Aug 14:13524585241264472. doi: 10.1177/13524585241264472.
     PubMed    
     
     
     
181. MONTOBBIO N, Carmisciano L, Signori A, Ponzano M, et al
     Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis.
     Mult Scler. 2024 Aug 14:13524585241243157. doi: 10.1177/13524585241243157.
     PubMed     Abstract available
     
     
     
182. LAPUCCI C, Frau J, Cocco E, Coghe G, et al
     Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
     Mult Scler. 2024 Aug 14:13524585241266509. doi: 10.1177/13524585241266509.
     PubMed     Abstract available
     
     
     
183. KALINCIK T
     The era of harmonised disability outcomes in multiple sclerosis.
     Mult Scler. 2024 Aug 14:13524585241266517. doi: 10.1177/13524585241266517.
     PubMed    
     
     
     
184. CAMPAGNA MP, Lechner-Scott J, Taylor BV, Havrdova EK, et al
     Re: Genetics of multiple sclerosis severity: The importance of statistical power in replication studies and Re: From discovery to replication: Power and definitions matter for multiple sclerosis severity.
     Mult Scler. 2024 Aug 14:13524585241264469. doi: 10.1177/13524585241264469.
     PubMed    
     
     
     
185. BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
     Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
     Mult Scler. 2024 Aug 7:13524585241267257. doi: 10.1177/13524585241267257.
     PubMed     Abstract available
     
     
     
186. CAMPBELL JA, Simpson-Yap S, Taylor BV, van der Mei I, et al
     Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021.
     Mult Scler. 2024 Aug 5:13524585241265890. doi: 10.1177/13524585241265890.
     PubMed     Abstract available
     
     
     
187. CAMERON MH, Hildebrand A, Hugos C, Wooliscroft L, et al
     A walking aid selection, training, and education program (ADSTEP) to prevent falls in multiple sclerosis: A randomized controlled trial.
     Mult Scler. 2024 Aug 5:13524585241265031. doi: 10.1177/13524585241265031.
     PubMed     Abstract available
     
     
     
188. DVORAK E, Levy S, Anderson JR, Sumowski JF, et al
     Phonemic processing is below expectations and linked to word-finding difficulty in multiple sclerosis.
     Mult Scler. 2024 Aug 5:13524585241259648. doi: 10.1177/13524585241259648.
     PubMed     Abstract available
     
     
     
189. ROOS I, Sharmin S, Malpas C, Ozakbas S, et al
     Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
     Mult Scler. 2024 Aug 1:13524585241267211. doi: 10.1177/13524585241267211.
     PubMed     Abstract available
     
     
     
190. VOSKUHL R
     All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Yes.
     Mult Scler. 2024;30:1107-1109.
     PubMed    
     
     
     
191. ZHANG Q, Noyce AJ, Robson J, Giovannoni G, et al
     No association between oral contraceptive exposure and subsequent MS: A population-based nested case-control study in primary care.
     Mult Scler. 2024;30:1221-1226.
     PubMed     Abstract available
     
     
     
192. CHEEMA S, Matharu M
     Facial pain in MS: When to think of trigeminal autonomic cephalalgia.
     Mult Scler. 2024;30:1230-1231.
     PubMed    
     
     
     July 2024
193. BEBO B, Coetzee T, Gray E, Helme A, et al
     The first global landscape analysis of multiple sclerosis research funding.
     Mult Scler. 2024 Jul 31:13524585241265961. doi: 10.1177/13524585241265961.
     PubMed     Abstract available
     
     
     
194. PROSPERINI L, Ruggieri S, Haggiag S, Tortorella C, et al
     Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context.
     Mult Scler. 2024 Jul 31:13524585241266180. doi: 10.1177/13524585241266180.
     PubMed     Abstract available
     
     
     
195. ROMOZZI M, Vollono C, Calabresi P, Iorio R, et al
     Epilepsia Partialis Continua as a manifestation of aquaporin-4 autoimmunity.
     Mult Scler. 2024 Jul 30:13524585241261535. doi: 10.1177/13524585241261535.
     PubMed     Abstract available
     
     
     
196. CARNERO CONTENTTI E
     Expanding the spectrum of NMOSD: New cases of autoimmune epilepsy and meningoencephalitis.
     Mult Scler. 2024 Jul 30:13524585241261545. doi: 10.1177/13524585241261545.
     PubMed    
     
     
     
197. SIDHU NK, Proudfoot H, Adan HM, Fawson S, et al
     Diversity and inclusion in behavioural intervention trials in multiple sclerosis: A commentary.
     Mult Scler. 2024 Jul 26:13524585241248279. doi: 10.1177/13524585241248279.
     PubMed    
     
     
     
198. STRIDH P, Huang J, Kockum I
     From discovery to replication: Power and definitions matter for multiple sclerosis severity.
     Mult Scler. 2024 Jul 26:13524585241265021. doi: 10.1177/13524585241265021.
     PubMed    
     
     
     
199. MOHAN SD, Peterson S, Brenton JN, Carmichael SL, et al
     Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis.
     Mult Scler. 2024;30:1056-1065.
     PubMed     Abstract available
     
     
     
200. ZEINEDDINE M, Al-Roughani R, Farouk Ahmed S, Khoury S, et al
     Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
     Mult Scler. 2024;30:1026-1035.
     PubMed     Abstract available
     
     
     
201. UZAWA A, Mori M, Masuda H, Muto M, et al
     Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody-associated disease.
     Mult Scler. 2024;30:977-982.
     PubMed     Abstract available
     
     
     
202. DE JONG DJ, Strijbis EM, Killestein J
     Information from ecological momentary assessments lead to over-medicalization: Commentary.
     Mult Scler. 2024;30:972-973.
     PubMed    
     
     
     
203. PREZIOSA P, Rocca MA, Filippi M
     Information from ecological momentary assessments leads to over-medicalization: No.
     Mult Scler. 2024;30:970-972.
     PubMed    
     
     
     
204. HOGESTOL EA, Berg-Hansen P
     Information from ecological momentary assessments lead to over-medicalization: Yes.
     Mult Scler. 2024;30:968-969.
     PubMed    
     
     
     
205. LEVIT E, Ren Z, Gonzenbach V, Azevedo CJ, et al
     Choroid plexus volume differentiates MS from its mimics.
     Mult Scler. 2024;30:1072-1076.
     PubMed     Abstract available
     
     
     
206. MEALLI F, Mattei A, Mariottini A, Massacesi L, et al
     Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study.
     Mult Scler. 2024;30:1077-1080.
     PubMed     Abstract available
     
     
     
207. COBAN H
     Tick-borne illnesses in patients treated with B-cell depleting agents: Considerations for neurologists.
     Mult Scler. 2024;30:1084-1085.
     PubMed    
     
     
     
208. MCMURRAN CE, Mukherjee T, Brown JWL, Coles AJ, et al
     Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.
     Mult Scler. 2024;30:1066-1071.
     PubMed     Abstract available
     
     
     June 2024
209. MOROZUMI T, Preziosa P, Meani A, Pessina G, et al
     Brain and cervical spinal cord MRI correlates of sensorimotor impairment in patients with multiple sclerosis.
     Mult Scler. 2024 Jun 24:13524585241260145. doi: 10.1177/13524585241260145.
     PubMed     Abstract available
     
     
     
210. MALLUCCI G, Monti MC, Ponzio M, Borrelli P, et al
     Impact of multiple sclerosis comorbidities on quality of life and job activity.
     Mult Scler. 2024 Jun 24:13524585241260550. doi: 10.1177/13524585241260550.
     PubMed     Abstract available
     
     
     
211. SCARAMOZZA M, Chiesa PA, Zajac L, Sun Z, et al
     Konectom cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.
     Mult Scler. 2024 Jun 24:13524585241259650. doi: 10.1177/13524585241259650.
     PubMed     Abstract available
     
     
     
212. MAGYARI M
     All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: No.
     Mult Scler. 2024 Jun 22:13524585241254987. doi: 10.1177/13524585241254987.
     PubMed    
     
     
     
213. PETHERAM K, Dobson R
     All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Commentary.
     Mult Scler. 2024 Jun 22:13524585241254989. doi: 10.1177/13524585241254989.
     PubMed    
     
     
     
214. CONTE WL
     Addressing LGBTQ+ health equity and disparities in multiple sclerosis: A call for research and action.
     Mult Scler. 2024 Jun 19:13524585241263281. doi: 10.1177/13524585241263281.
     PubMed     Abstract available
     
     
     
215. MORROW SA, Hancock L
     Monitoring cognitive functioning in multiple sclerosis will trigger anxiety in patients: Commentary.
     Mult Scler. 2024 Jun 16:13524585241261200. doi: 10.1177/13524585241261200.
     PubMed    
     
     
     
216. BALSHI A, Manning N, Dempsey J, Kumbar S, et al
     Altered lymphocyte profiles and herpes zoster infections in patients with multiple sclerosis on natalizumab.
     Mult Scler. 2024 Jun 16:13524585241260537. doi: 10.1177/13524585241260537.
     PubMed     Abstract available
     
     
     
217. KOLSCHE T, Willison AG, Meuth SG, Pawlitzki M, et al
     Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.
     Mult Scler. 2024 Jun 15:13524585241260564. doi: 10.1177/13524585241260564.
     PubMed    
     
     
     
218. DALLA COSTA G, Leocani L, Pisa M, Croese T, et al
     Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.
     Mult Scler. 2024 Jun 14:13524585241260977. doi: 10.1177/13524585241260977.
     PubMed     Abstract available
     
     
     
219. KRIJNEN EA, Kouwenhoven RM, Noteboom S, Barkhof F, et al
     Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.
     Mult Scler. 2024 Jun 13:13524585241260968. doi: 10.1177/13524585241260968.
     PubMed     Abstract available
     
     
     
220. SMETS I, Versteegh M, Huygens S, Wokke B, et al
     Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model.
     Mult Scler. 2024 Jun 10:13524585241258692. doi: 10.1177/13524585241258692.
     PubMed     Abstract available
     
     
     
221. NOVA A, Di Caprio G, Bernardinelli L, Fazia T, et al
     Genetic and early life factors influence on time-to-multiple sclerosis diagnosis: A UK Biobank study.
     Mult Scler. 2024 Jun 7:13524585241257205. doi: 10.1177/13524585241257205.
     PubMed     Abstract available
     
     
     
222. BORRELLI S, Guisset F, Vanden Bulcke C, Stolting A, et al
     Enlarged perivascular spaces are associated with brain microangiopathy and aging in multiple sclerosis.
     Mult Scler. 2024 Jun 7:13524585241256881. doi: 10.1177/13524585241256881.
     PubMed     Abstract available
     
     
     
223. PONZANO M, Signori A, Bellavia A, Carbone A, et al
     Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic review.
     Mult Scler. 2024 Jun 7:13524585241254283. doi: 10.1177/13524585241254283.
     PubMed     Abstract available
     
     
     
224. FOSTER MA, Prados F, Collorone S, Kanber B, et al
     Improving explanation of motor disability with diffusion-based graph metrics at onset of the first demyelinating event.
     Mult Scler. 2024;30:800-811.
     PubMed     Abstract available
     
     
     
225. MONTOBBIO N, Bovis F, Signori A, Ponzano M, et al
     Therapeutic lag: Is treatment effect delayed in progressive MS?
     Mult Scler. 2024;30:843-846.
     PubMed     Abstract available
     
     
     
226. PFEUFFER S
     Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas.
     Mult Scler. 2024;30:897-898.
     PubMed    
     
     
     May 2024
227. AKBARIAN F, Rossi C, Costers L, D'hooghe MB, et al
     Stimulus-related modulation in the 1/f spectral slope suggests an impaired inhibition during a working memory task in people with multiple sclerosis.
     Mult Scler. 2024 May 20:13524585241253777. doi: 10.1177/13524585241253777.
     PubMed     Abstract available
     
     
     
228. MENG D, Sacco R, Disanto G, Widmer F, et al
     Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
     Mult Scler. 2024 May 20:13524585241250199. doi: 10.1177/13524585241250199.
     PubMed     Abstract available
     
     
     
229. LEBRUN-FRENAY C, Okuda DT
     Time to move past typical syndromes in the diagnosis of multiple sclerosis.
     Mult Scler. 2024 May 15:13524585241253519. doi: 10.1177/13524585241253519.
     PubMed    
     
     
     
230. WICKLEIN R, Kreitner L, Wild A, Aly L, et al
     Retinal small vessel pathology is associated with disease burden in multiple sclerosis.
     Mult Scler. 2024 May 15:13524585241247775. doi: 10.1177/13524585241247775.
     PubMed     Abstract available
     
     
     
231. NAIZER H, Wozny J, Krause TM, Huson E, et al
     Trends in central nervous system-active polypharmacy among people with multiple sclerosis.
     Mult Scler. 2024 May 15:13524585241251986. doi: 10.1177/13524585241251986.
     PubMed     Abstract available
     
     
     
232. HEWARD KD, Roy-Hewitson C, Solomon AJ
     Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria.
     Mult Scler. 2024 May 15:13524585241253513. doi: 10.1177/13524585241253513.
     PubMed     Abstract available
     
     
     
233. COLLORONE S, Coll L, Lorenzi M, Llado X, et al
     Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis.
     Mult Scler. 2024 May 13:13524585241249422. doi: 10.1177/13524585241249422.
     PubMed     Abstract available
     
     
     
234. DAGNEW B, Laslett LL, Honan CA, Blizzard L, et al
     The association of comorbidities with sleep quality among Australians with multiple sclerosis: Insights from the Australian Multiple Sclerosis Longitudinal Study.
     Mult Scler. 2024 May 13:13524585241248278. doi: 10.1177/13524585241248278.
     PubMed     Abstract available
     
     
     
235. ANDERSEN ML, Jolving LR, Iachina M, Stenager E, et al
     Children born preterm or small for gestational age to mothers with multiple sclerosis: Do these children have an increased risk of infections in early life?
     Mult Scler. 2024 May 8:13524585241249077. doi: 10.1177/13524585241249077.
     PubMed     Abstract available
     
     
     
236. PROSPERINI L, Haggiag S
     Late-onset multiple sclerosis from a different angle.
     Mult Scler. 2024 May 8:13524585241249901. doi: 10.1177/13524585241249901.
     PubMed    
     
     
     
237. PORTACCIO E, Grossi P, Bellomi F, Bianchi V, et al
     Meaningful cognitive change for the Minimal Assessment of Cognitive Function in Multiple Sclerosis.
     Mult Scler. 2024 May 8:13524585241249084. doi: 10.1177/13524585241249084.
     PubMed     Abstract available
     
     
     April 2024
238. FEINSTEIN A
     Depression is a core symptom of multiple sclerosis.
     Mult Scler. 2024 Apr 30:13524585241245637. doi: 10.1177/13524585241245637.
     PubMed    
     
     
     
239. HANCOCK LM
     Depression is a core symptom of multiple sclerosis: Yes.
     Mult Scler. 2024 Apr 30:13524585241249564. doi: 10.1177/13524585241249564.
     PubMed    
     
     
     
240. LEAVITT VM
     Depression is a core symptom of multiple sclerosis: NO.
     Mult Scler. 2024 Apr 30:13524585241245653. doi: 10.1177/13524585241245653.
     PubMed    
     
     
     
241. MANUEL AM, Gottlieb A, Freeman L, Zhao Z, et al
     Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data.
     Mult Scler. 2024 Apr 25:13524585241240398. doi: 10.1177/13524585241240398.
     PubMed     Abstract available
     
     
     
242. BIANCHI A, Cortese R, Prados F, Tur C, et al
     Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease.
     Mult Scler. 2024 Apr 22:13524585241240420. doi: 10.1177/13524585241240420.
     PubMed     Abstract available
     
     
     
243. NOVAK F, Bajwa HM, Ostergaard K, Berg JM, et al
     Extended interval dosing with ocrelizumab in multiple sclerosis.
     Mult Scler. 2024 Apr 22:13524585241245296. doi: 10.1177/13524585241245296.
     PubMed     Abstract available
     
     
     
244. OKUDA DT, Lebrun-Frenay C
     Radiologically isolated syndrome in the spectrum of multiple sclerosis.
     Mult Scler. 2024 Apr 15:13524585241245306. doi: 10.1177/13524585241245306.
     PubMed     Abstract available
     
     
     
245. CHITNIS T, Banwell B, Kappos L, Arnold DL, et al
     Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
     Mult Scler. 2024 Apr 15:13524585241242050. doi: 10.1177/13524585241242050.
     PubMed     Abstract available
     
     
     
246. HEMOND CC, Solomon AJ
     Multiple sclerosis can be diagnosed solely with dissemination in space: No.
     Mult Scler. 2024 Apr 14:13524585241245297. doi: 10.1177/13524585241245297.
     PubMed    
     
     
     
247. MCGINLEY MP, Cohen JA
     Multiple sclerosis can be diagnosed solely with dissemination in space: Commentary.
     Mult Scler. 2024 Apr 14:13524585241245319. doi: 10.1177/13524585241245319.
     PubMed    
     
     
     
248. TOOSY AT, Barkhof F
     Multiple sclerosis can be diagnosed solely with dissemination in space: Yes.
     Mult Scler. 2024 Apr 14:13524585241245313. doi: 10.1177/13524585241245313.
     PubMed    
     
     
     
249. OZTURK B, Taskiran E, Demir S, Tuncer MA, et al
     Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study.
     Mult Scler. 2024 Apr 14:13524585241245318. doi: 10.1177/13524585241245318.
     PubMed     Abstract available
     
     
     
250. SCHNEIDER M, Kramer J, Banks A, Moses H, et al
     New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.
     Mult Scler. 2024 Apr 11:13524585241242027. doi: 10.1177/13524585241242027.
     PubMed     Abstract available
     
     
     
251. MOCCIA M, Terracciano D, Brescia Morra V, Castaldo G, et al
     Neurofilament in clinical practice: Is the multiple sclerosis community ready?
     Mult Scler. 2024 Apr 11:13524585241246536. doi: 10.1177/13524585241246536.
     PubMed    
     
     
     
252. KWON S, Han KD, Jung JH, Cho EB, et al
     Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
     Mult Scler. 2024 Apr 1:13524585241237093. doi: 10.1177/13524585241237093.
     PubMed     Abstract available
     
     
     
253. ALOISI F, Salvetti M
     EBV infection drives MS pathology: Yes.
     Mult Scler. 2024;30.
     PubMed    
     
     
     
254. CORTESE M, Ascherio A
     EBV infection drives MS pathology: Commentary.
     Mult Scler. 2024;30.
     PubMed    
     
     
     
255. 'T HART BA, van Luijn MM
     EBV infection drives MS pathology: No.
     Mult Scler. 2024;30.
     PubMed    
     
     
     
256. TUR C, Battiston M, Yiannakas MC, Collorone S, et al
     What contributes to disability in progressive MS? A brain and cervical cord-matched quantitative MRI study.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
257. REEVES JA, Mohebbi M, Wicks T, Salman F, et al
     Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
258. KLISTORNER S, Barnett MH, Wang C, Parratt J, et al
     Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     
259. SBRAGIA E, Boffa G, Varaldo R, Raiola AM, et al
     An aggressive form of MOGAD treated with aHSCT: A case report.
     Mult Scler. 2024;30.
     PubMed     Abstract available
     
     
     March 2024
260. PAPPOLLA A, Auger C, Sao-Aviles A, Tur C, et al
     Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
     Mult Scler. 2024 Mar 29:13524585241240653. doi: 10.1177/13524585241240653.
     PubMed     Abstract available
     
     
     
261. SIMPSON AC, Hu C, Mowry EM, Naismith RT, et al
     Structural MRI measures are associated with fatigue severity and persistence in a large, real-world cohort of people with multiple sclerosis.
     Mult Scler. 2024 Mar 25:13524585241239473. doi: 10.1177/13524585241239473.
     PubMed     Abstract available
     
     
     
262. SORENSEN PS, Bramow S, Magyari M, Werdelin L, et al
     Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research.
     Mult Scler. 2024 Mar 24:13524585241239506. doi: 10.1177/13524585241239506.
     PubMed     Abstract available
     
     
     
263. MAILLART E, Redolfi S, Louapre C, Houot M, et al
     Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort.
     Mult Scler. 2024 Mar 22:13524585241238840. doi: 10.1177/13524585241238840.
     PubMed     Abstract available
     
     
     
264. CAMPAGNA MP, Havrdova EK, Horakova D, Izquierdo G, et al
     No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.
     Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406.
     PubMed     Abstract available
     
     
     
265. HJALGRIM H, Rostgaard K
     Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit?
     Mult Scler. 2024 Mar 21:13524585241237708. doi: 10.1177/13524585241237708.
     PubMed    
     
     
     
266. GOLDACRE R
     Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003-2023.
     Mult Scler. 2024 Mar 21:13524585241237707. doi: 10.1177/13524585241237707.
     PubMed     Abstract available
     
     
     
267. JOHNSSON M, Stenberg YT, Farman HH, Blennow K, et al
     Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
     Mult Scler. 2024 Mar 13:13524585241237388. doi: 10.1177/13524585241237388.
     PubMed     Abstract available
     
     
     
268. NAKAMURA K, Sun Z, Hara-Cleaver C, Bodhinathan K, et al
     Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
     Mult Scler. 2024 Mar 12:13524585241235055. doi: 10.1177/13524585241235055.
     PubMed     Abstract available
     
     
     
269. EHLING R, Seebacher B, Brenneis C
     Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review.
     Mult Scler. 2024 Mar 11:13524585241234789. doi: 10.1177/13524585241234789.
     PubMed    
     
     
     
270. HILLERT J, Bove R, Haddad LB, Hellwig K, et al
     Expert opinion on the use of contraception in people with multiple sclerosis.
     Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
     PubMed     Abstract available
     
     
     
271. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
     Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
     Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
     PubMed     Abstract available
     
     
     
272. KUBICKI K, Stefoski D
     Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.
     Mult Scler. 2024 Mar 8:13524585241235539. doi: 10.1177/13524585241235539.
     PubMed     Abstract available
     
     
     
273. MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al
     Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
     Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
     PubMed     Abstract available
     
     
     
274. GIULIANI G, Zilli C, Caramia F, Di Piero V, et al
     SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia.
     Mult Scler. 2024 Mar 1:13524585241235535. doi: 10.1177/13524585241235535.
     PubMed     Abstract available
     
     
     
275. ROCCHI C, Forcadela M, Kelly P, Linaker S, et al
     The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis.
     Mult Scler. 2024;30:345-356.
     PubMed     Abstract available
     
     
     February 2024
276. AFZAL RM, Romme Christensen J, Gynthersen RMM, Lebech AM, et al
     Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report.
     Mult Scler. 2024 Feb 29:13524585241235542. doi: 10.1177/13524585241235542.
     PubMed     Abstract available
     
     
     
277. KARI S, Bucciarelli F, Angles T, Oster AC, et al
     Increased levels of circulating soluble CD226 in multiple sclerosis.
     Mult Scler. 2024 Feb 29:13524585241234489. doi: 10.1177/13524585241234489.
     PubMed     Abstract available
     
     
     
278. HEESEN C, Luhmann D
     Reply: Mobile health interventions in multiple sclerosis: A systematic review.
     Mult Scler. 2024 Feb 29:13524585241234777. doi: 10.1177/13524585241234777.
     PubMed    
     
     
     
279. LIM TRU, Kumaran SP, Suthiphosuwan S, Espiritu AI, et al
     Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
     Mult Scler. 2024 Feb 28:13524585241228426. doi: 10.1177/13524585241228426.
     PubMed     Abstract available
     
     
     
280. NAKKEN O, Aarseth JH, Wergeland S, Stigum H, et al
     BCG vaccination and multiple sclerosis risk: A Norwegian cohort study.
     Mult Scler. 2024 Feb 27:13524585241230440. doi: 10.1177/13524585241230440.
     PubMed     Abstract available
     
     
     
281. MILLER AE
     Dissemination in time as a requirement for diagnosis of multiple sclerosis: Time for a change?
     Mult Scler. 2024 Feb 27:13524585241233999. doi: 10.1177/13524585241233999.
     PubMed     Abstract available
     
     
     
282. KRIEGER SC, Sinks S, Huang F, Steverson J, et al
     The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis.
     Mult Scler. 2024 Feb 26:13524585241232274. doi: 10.1177/13524585241232274.
     PubMed     Abstract available
     
     
     
283. BOAVENTURA M, Sastre-Garriga J, Rimkus CM, Rovira A, et al
     T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.
     Mult Scler. 2024 Feb 22:13524585241233448. doi: 10.1177/13524585241233448.
     PubMed     Abstract available
     
     
     
284. EMMA C, Vesela P, Kay P, Huseyin H, et al
     Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
     Mult Scler. 2024 Feb 22:13524585241232277. doi: 10.1177/13524585241232277.
     PubMed     Abstract available
     
     
     
285. ERCAN MB, Kocer B, Altiparmak T, Arslan I, et al
     Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
     Mult Scler. 2024 Feb 22:13524585241231655. doi: 10.1177/13524585241231655.
     PubMed    
     
     
     
286. JALALEDDINI K, Bermel RA, Talente B, Weinstein D, et al
     A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
     Mult Scler. 2024 Feb 19:13524585241227372. doi: 10.1177/13524585241227372.
     PubMed     Abstract available
     
     
     
287. ROCCA MA, D'Amore G, Valsasina P, Tedone N, et al
     2.5-Year changes of connectivity dynamism are relevant for physical and cognitive deterioration in multiple sclerosis.
     Mult Scler. 2024 Feb 19:13524585241231155. doi: 10.1177/13524585241231155.
     PubMed     Abstract available
     
     
     
288. ROVARIS M, Toselli E, Mendozzi L, Di Tella S, et al
     Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study.
     Mult Scler. 2024 Feb 19:13524585241230236. doi: 10.1177/13524585241230236.
     PubMed     Abstract available
     
     
     
289. HOANG P, Sturnieks DL, Butler A, Chaplin C, et al
     A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial.
     Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360.
     PubMed     Abstract available
     
     
     
290. COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al
     Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
     Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880.
     PubMed     Abstract available
     
     
     
291. PATEL S, Rafferty S, Aquino L, Chadha S, et al
     VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis.
     Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739.
     PubMed     Abstract available
     
     
     
292. KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al
     Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
     Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665.
     PubMed     Abstract available
     
     
     
293. MOTL RW, Russell DI, Pilutti LA, Metse AP, et al
     Drop-out, adherence, and compliance in randomized controlled trials of exercise training in multiple sclerosis: Short report.
     Mult Scler. 2024 Feb 9:13524585241229332. doi: 10.1177/13524585241229332.
     PubMed     Abstract available
     
     
     
294. BELLUCCI G, Buscarinu MC, Renie R, Rinaldi V, et al
     Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach.
     Mult Scler. 2024 Feb 9:13524585241227119. doi: 10.1177/13524585241227119.
     PubMed     Abstract available
     
     
     
295. ZIAEI A, Solomon O, Casper TC, Waltz M, et al
     Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis.
     Mult Scler. 2024 Feb 9:13524585231224685. doi: 10.1177/13524585231224685.
     PubMed     Abstract available
     
     
     
296. GILMARTIN CG, Hoyle N, Garjani A, Dixon T, et al
     Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
     Mult Scler. 2024 Feb 7:13524585231225711. doi: 10.1177/13524585231225711.
     PubMed     Abstract available
     
     
     
297. MCGINLEY MP, Manouchehrinia A
     The landscape of multiple sclerosis registries: Strengths and limitations.
     Mult Scler. 2024 Feb 6:13524585241228746. doi: 10.1177/13524585241228746.
     PubMed    
     
     
     
298. VUKUSIC S, Bourre B, Casey R, Deiva K, et al
     The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years-Protocol, recruitment status, and baseline characteristics.
     Mult Scler. 2024;30:216-226.
     PubMed     Abstract available
     
     
     
299. GHAJARZADEH M, Fitzgerald KC, Mowry EM, Nourbakhsh B, et al
     Association between demographics, socioeconomics, and disease-related factors and the perception of stigma in people with MS.
     Mult Scler. 2024;30:238-246.
     PubMed     Abstract available
     
     
     
300. SCHNEIDER R, Brand-Arzamendi K, Reynold Lim T, Lee LE, et al
     Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome.
     Mult Scler. 2024;30:156-165.
     PubMed     Abstract available
     
     
     
301. GONZALEZ CALDITO N, Graham EL, Grebenciucova E
     Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth.
     Mult Scler. 2024;30:272-274.
     PubMed     Abstract available
     
     
     
302. LANGDON D
     Neuropsychological assessment in MS is outdated and in need for innovation: NO.
     Mult Scler. 2024;30:152-153.
     PubMed    
     
     
     January 2024
303. NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al
     Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
     Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702.
     PubMed     Abstract available
     
     
     
304. SWITAL M, Drouin J, Miranda S, Bakchine S, et al
     Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
     Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395.
     PubMed     Abstract available
     
     
     
305. MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al
     White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study.
     Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681.
     PubMed     Abstract available
     
     
     
306. HIRT J, Janiaud P, Dublin P, Nicoletti GJ, et al
     Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
     Mult Scler. 2024 Jan 22:13524585231221938. doi: 10.1177/13524585231221938.
     PubMed     Abstract available
     
     
     
307. CAMERLINGO S, Rubinstein F, Celia Ysrraelit M, Correale J, et al
     Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
     Mult Scler. 2024 Jan 21:13524585231219138. doi: 10.1177/13524585231219138.
     PubMed     Abstract available
     
     
     
308. JEANTIN L, Januel E, Labauge P, Maillart E, et al
     COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
     Mult Scler. 2024 Jan 21:13524585231218149. doi: 10.1177/13524585231218149.
     PubMed     Abstract available
     
     
     
309. TENI FS, Machado A, Fink K, Gyllensten H, et al
     Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
     Mult Scler. 2024 Jan 19:13524585231225929. doi: 10.1177/13524585231225929.
     PubMed     Abstract available
     
     
     
310. VIDAL-JORDANA A, Sastre-Garriga J, Tintore M, Rovira A, et al
     Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions.
     Mult Scler. 2024 Jan 19:13524585231225848. doi: 10.1177/13524585231225848.
     PubMed     Abstract available
     
     
     
311. TOOROP AA, Noteboom S, Steenwijk MD, Gravendeel JW, et al
     Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
     Mult Scler. 2024 Jan 18:13524585231225855. doi: 10.1177/13524585231225855.
     PubMed     Abstract available
     
     
     
312. DAS J, Rog DJ, Middleton R, Rodgers JW, et al
     University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register.
     Mult Scler. 2024 Jan 17:13524585231221411. doi: 10.1177/13524585231221411.
     PubMed     Abstract available
     
     
     
313. PORTACCIO E, Iaffaldano P
     Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggers.
     Mult Scler. 2024 Jan 11:13524585231224667. doi: 10.1177/13524585231224667.
     PubMed    
     
     
     
314. FRAMKE E, Thygesen LC, Malmborg M, Schou M, et al
     Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark.
     Mult Scler. 2024 Jan 11:13524585231221415. doi: 10.1177/13524585231221415.
     PubMed     Abstract available
     
     
     
315. MOTYL J
     Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs.
     Mult Scler. 2024 Jan 9:13524585231221409. doi: 10.1177/13524585231221409.
     PubMed    
     
     
     
316. MORROW SA
     Response to letter to the editor "Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs".
     Mult Scler. 2024 Jan 9:13524585231221412. doi: 10.1177/13524585231221412.
     PubMed    
     
     
     
317. VENET M, Lepine A, Maarouf A, Biotti D, et al
     Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
     Mult Scler. 2024 Jan 2:13524585231223069. doi: 10.1177/13524585231223069.
     PubMed     Abstract available
     
     
     
318. WEINSHENKER BG
     MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Commentary.
     Mult Scler. 2024;30:23-24.
     PubMed    
     
     
     
319. CARNERO CONTENTTI E, Wingerchuk DM
     MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes.
     Mult Scler. 2024;30:19-21.
     PubMed    
     
     
     
320. MARIGNIER R, Cree BA
     MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: No.
     Mult Scler. 2024;30:21-23.
     PubMed    
     
     
     
321. VAN LAETHEM D, Denissen S, Costers L, Descamps A, et al
     The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment.
     Mult Scler. 2024;30:121-130.
     PubMed     Abstract available
     
     
     
322. HUGOS CL, Joos SK, Perumean-Chaney SE, Cutter GR, et al
     Stretching is not essential for managing MS spasticity: A randomized controlled trial.
     Mult Scler. 2024;30:89-102.
     PubMed     Abstract available
     
     
     
323. DE GIER M, Beckerman H, Twisk JW, Knoop H, et al
     Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial.
     Mult Scler. 2024;30:71-79.
     PubMed     Abstract available
     
     
     
324. GUO RY, Wang WY, Huang JY, Jia Z, et al
     Deciphering prognostic indicators in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: An integrative review of demographic and laboratory factors.
     Mult Scler. 2024;30:7-15.
     PubMed     Abstract available
     
     
     
325. WRIGHT SL, Thompson AJ
     Managing patients with late-onset neutropenia during treatment with ocrelizumab.
     Mult Scler. 2024;30:134.
     PubMed    
     
     
     
326. KOCH-HENRIKSEN NI, Thygesen LC, Sorensen PS, Magyari M, et al
     Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS.
     Mult Scler. 2024;30:113-120.
     PubMed     Abstract available
     
     
     December 2023
327. PARCIAK T, Geys L, Helme A, van der Mei I, et al
     Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.
     Mult Scler. 2023 Dec 23:13524585231216004. doi: 10.1177/13524585231216004.
     PubMed     Abstract available
     
     
     
328. DOBSON R, Holden D, Vickaryous N, Bestwick J, et al
     A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
     Mult Scler. 2023 Dec 22:13524585231215268. doi: 10.1177/13524585231215268.
     PubMed     Abstract available
     
     
     
329. NAISMITH RT, Cohen JA, Bar-Or A, Comi G, et al
     Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
     Mult Scler. 2023 Dec 21:13524585231216854. doi: 10.1177/13524585231216854.
     PubMed     Abstract available
     
     
     
330. TAZZA F, Schiavi S, Leveraro E, Cellerino M, et al
     Clinical and radiological correlates of apathy in multiple sclerosis.
     Mult Scler. 2023 Dec 14:13524585231217918. doi: 10.1177/13524585231217918.
     PubMed     Abstract available
     
     
     
331. DABOUL L, O'Donnell CM, Amin M, Rodrigues P, et al
     A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.
     Mult Scler. 2023 Dec 13:13524585231214360. doi: 10.1177/13524585231214360.
     PubMed     Abstract available
     
     
     
332. DALLA COSTA G, Nos C, Zabalza A, Buron M, et al
     A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.
     Mult Scler. 2023 Dec 12:13524585231214362. doi: 10.1177/13524585231214362.
     PubMed     Abstract available
     
     
     
333. BRUCE JM, Cozart JS, Shook RP, Befort C, et al
     Modifying diet and exercise in multiple sclerosis (MoDEMS): A randomized controlled trial for behavioral weight loss in adults with multiple sclerosis and obesity.
     Mult Scler. 2023;29:1860-1871.
     PubMed     Abstract available
     
     
     
334. SACCO S, Virupakshaiah A, Papinutto N, Schoeps VA, et al
     Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease.
     Mult Scler. 2023;29:1736-1747.
     PubMed     Abstract available
     
     
     
335. LUBLIN FD
     Worsening MS-A reappraisal of how we characterize the MS disease course.
     Mult Scler. 2023;29:1699-1700.
     PubMed    
     
     
     
336. SAMADZADEH S, Olesen MN, Wirenfeldt M, Moller S, et al
     Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
     Mult Scler. 2023;29:1721-1735.
     PubMed     Abstract available
     
     
     
337. PROSCHMANN U, Mueller-Enz M, Woopen C, Katoul Al Rahbani G, et al
     Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
     Mult Scler. 2023;29:1849-1859.
     PubMed     Abstract available
     
     
     
338. MORROW SA, Weinstock ZL, Mirmosayyeb O, Conway D, et al
     Detecting isolated cognitive relapses in persons with MS.
     Mult Scler. 2023;29:1786-1794.
     PubMed     Abstract available
     
     
     
339. ENGELS D, Havla J, Forderreuther S, Kumpfel T, et al
     Therapy challenges for NMOSD in a patient with HIV.
     Mult Scler. 2023;29:1872-1875.
     PubMed     Abstract available
     
     
     November 2023
340. MATTIESING RM, Kramer E, Strijbis EM, Brouwer I, et al
     Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
     Mult Scler. 2023 Nov 29:13524585231212879. doi: 10.1177/13524585231212879.
     PubMed     Abstract available
     
     
     
341. ZHAO T, Taylor BV, Campbell JA, Palmer AJ, et al
     The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022.
     Mult Scler. 2023 Nov 24:13524585231213230. doi: 10.1177/13524585231213230.
     PubMed     Abstract available
     
     
     
342. MONTEIRO IR, Moccia M
     Mobile health interventions in multiple sclerosis: Bringing empowerment into clinical practice.
     Mult Scler. 2023 Nov 20:13524585231214879. doi: 10.1177/13524585231214879.
     PubMed    
     
     
     
343. CASTANO-AMORES C, Nieto-Gomez P
     The crossroads of multiple sclerosis and cancer: Urgent call for clinical direction.
     Mult Scler. 2023 Nov 20:13524585231214171. doi: 10.1177/13524585231214171.
     PubMed    
     
     
     
344. LADAKIS DC, Reyes-Mantilla MI, Gadani SP, Mace JW, et al
     Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
     Mult Scler. 2023 Nov 20:13524585231213164. doi: 10.1177/13524585231213164.
     PubMed     Abstract available
     
     
     
345. NIELSEN NM, Frisch M, Gortz S, Stenager E, et al
     Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study.
     Mult Scler. 2023 Nov 19:13524585231208310. doi: 10.1177/13524585231208310.
     PubMed     Abstract available
     
     
     
346. BROCHET B, Solari A, Lechner-Scott J, Piehl F, et al
     Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
     Mult Scler. 2023 Nov 18:13524585231205962. doi: 10.1177/13524585231205962.
     PubMed     Abstract available
     
     
     
347. NICHOLSON S, Russo AW, Brewer K, Bien H, et al
     The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
     Mult Scler. 2023 Nov 10:13524585231204710. doi: 10.1177/13524585231204710.
     PubMed     Abstract available
     
     
     
348. BOU RJEILY N, Fitzgerald KC, Mowry EM
     Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
     Mult Scler. 2023 Nov 9:13524585231208311. doi: 10.1177/13524585231208311.
     PubMed     Abstract available
     
     
     
349. AMEZCUA L, Robers MV, Soneji D, Manouvakhova O, et al
     Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis.
     Mult Scler. 2023 Nov 9:13524585231209016. doi: 10.1177/13524585231209016.
     PubMed     Abstract available
     
     
     
350. VAN KEMPEN ZL, van Dam KP, Keijser JB, Stalman EW, et al
     Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
     Mult Scler. 2023 Nov 9:13524585231207761. doi: 10.1177/13524585231207761.
     PubMed     Abstract available
     
     
     
351. ZICCARDI S, Fuchs T, Dwyer MG, Zivadinov R, et al
     Cognitive phenotypes predict response to restorative cognitive rehabilitation in multiple sclerosis.
     Mult Scler. 2023 Nov 9:13524585231208331. doi: 10.1177/13524585231208331.
     PubMed     Abstract available
     
     
     
352. FEINSTEIN A
     The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial.
     Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524585231210178.
     PubMed    
     
     
     
353. CHASE E, Chen V, Martin K, Lane M, et al
     A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized controlled trial.
     Mult Scler. 2023;29:1659-1675.
     PubMed     Abstract available
     
     
     
354. WEINSTOCK ZL, Jaworski M 3rd, Dwyer MG, Jakimovski D, et al
     Auditory Test of Processing Speed: Preliminary validation of a smartphone-based test of mental speed.
     Mult Scler. 2023;29:1646-1658.
     PubMed     Abstract available
     
     
     
355. WISHART M, Everest MR, Morrow SA, Rose J, et al
     Establishing the consistency of a voice recognition symbol digit modalities test analogue.
     Mult Scler. 2023;29:1676-1679.
     PubMed     Abstract available
     
     
     
356. BOCCIA VD, Saitta L, Inglese M, Lapucci C, et al
     Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient.
     Mult Scler. 2023;29:1688-1692.
     PubMed     Abstract available
     
     
     October 2023
357. ONTANEDA D, Amezcua L
     Re-thinking race and geography in multiple sclerosis.
     Mult Scler. 2023 Oct 31:13524585231205969. doi: 10.1177/13524585231205969.
     PubMed    
     
     
     
358. SINGER BA, Arnold DL, Drulovic J, Freedman MS, et al
     Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
     Mult Scler. 2023 Oct 31:13524585231205708. doi: 10.1177/13524585231205708.
     PubMed     Abstract available
     
     
     
359. HEESEN C, Berger T, Riemann-Lorenz K, Krause N, et al
     Mobile health interventions in multiple sclerosis: A systematic review.
     Mult Scler. 2023 Oct 28:13524585231201089. doi: 10.1177/13524585231201089.
     PubMed     Abstract available
     
     
     
360. PORWAL MH, Obeidat AZ
     A closer look at reported colitis in association with multiple sclerosis treatments.
     Mult Scler. 2023 Oct 28:13524585231205964. doi: 10.1177/13524585231205964.
     PubMed    
     
     
     
361. LEARMONTH YC, P Herring M, Russell DI, Pilutti LA, et al
     Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis.
     Mult Scler. 2023 Oct 26:13524585231204459. doi: 10.1177/13524585231204459.
     PubMed     Abstract available
     
     
     
362. RAMARI C, Awadia Z, Bansi J, Casey B, et al
     The MoxFo initiative - outcomes: Outcome measures in studies of exercise training in multiple sclerosis; scoping review of reviews and classification according to the ICF framework.
     Mult Scler. 2023 Oct 26:13524585231204451. doi: 10.1177/13524585231204451.
     PubMed     Abstract available
     
     
     
363. DALGAS U, Riemenschneider M, Gold SM, Kalron A, et al
     The MoXFo initiative - study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis.
     Mult Scler. 2023 Oct 26:13524585231204456. doi: 10.1177/13524585231204456.
     PubMed     Abstract available
     
     
     
364. MANSOUBI M, Learmonth YC, Mayo N, Collet J, et al
     The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research.
     Mult Scler. 2023 Oct 26:13524585231204460. doi: 10.1177/13524585231204460.
     PubMed     Abstract available
     
     
     
365. ROSENKRANZ SC, Ploughman M, Hvid LG, Zimmer P, et al
     The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies.
     Mult Scler. 2023 Oct 26:13524585231204453. doi: 10.1177/13524585231204453.
     PubMed     Abstract available
     
     
     
366. MOTL RW, Casey B, Learmonth YC, Latimer-Cheung A, et al
     The MoXFo initiative - adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research.
     Mult Scler. 2023 Oct 26:13524585231204446. doi: 10.1177/13524585231204446.
     PubMed     Abstract available
     
     
     
367. ZHANG Y, Atkinson J, Burd CE, Graves J, et al
     Biological aging in multiple sclerosis.
     Mult Scler. 2023 Oct 25:13524585231204122. doi: 10.1177/13524585231204122.
     PubMed     Abstract available
     
     
     
368. BEREK K, Hegen H, Auer M, Barket R, et al
     Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
     Mult Scler. 2023 Oct 18:13524585231201093. doi: 10.1177/13524585231201093.
     PubMed     Abstract available
     
     
     
369. KOCH MW, Moral E, Brieva L, Mostert J, et al
     Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
     Mult Scler. 2023 Oct 13:13524585231202320. doi: 10.1177/13524585231202320.
     PubMed     Abstract available
     
     
     
370. DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
     Vaccination frequency in people newly diagnosed with multiple sclerosis.
     Mult Scler. 2023 Oct 13:13524585231199084. doi: 10.1177/13524585231199084.
     PubMed     Abstract available
     
     
     
371. REYES S, Otero-Romero S
     Rethinking vaccination in multiple sclerosis: The way forward.
     Mult Scler. 2023 Oct 3:13524585231204126. doi: 10.1177/13524585231204126.
     PubMed    
     
     
     
372. LAPUCCI C, Boccia VD, Sirito T, Cellerino M, et al
     Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series.
     Mult Scler. 2023 Oct 3:13524585231204121. doi: 10.1177/13524585231204121.
     PubMed     Abstract available
     
     
     
373. TIEPPO EMS, Silva GD, Silva TFFD, Araujo RS, et al
     Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process-Cohort study.
     Mult Scler. 2023 Oct 3:13524585231199323. doi: 10.1177/13524585231199323.
     PubMed     Abstract available
     
     
     
374. JACOBER SLS, Disanto G, Sacco R, Meng D, et al
     Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
     Mult Scler. 2023 Oct 3:13524585231199820. doi: 10.1177/13524585231199820.
     PubMed     Abstract available
     
     
     
375. UHER T, Adzima A, Srpova B, Noskova L, et al
     Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
376. WU Y, Geraldes R, Jurynczyk M, Palace J, et al
     Double-negative neuromyelitis optica spectrum disorder.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     
377. THOMPSON AJ, Moccia M, Amato MP, Calabresi PA, et al
     Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.
     Mult Scler. 2023;29.
     PubMed     Abstract available
     
     
     September 2023
378. ANDERSON JR, Fitzgerald KC, Murrough JW, Katz Sand IB, et al
     Depression symptoms and cognition in multiple sclerosis: Longitudinal evidence of a specific link to executive control.
     Mult Scler. 2023 Sep 29:13524585231198746. doi: 10.1177/13524585231198746.
     PubMed     Abstract available
     
     
     
379. CERDA-FUERTES N, Stoessel M, Mickeliunas G, Pless S, et al
     Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
     Mult Scler. 2023 Sep 29:13524585231198760. doi: 10.1177/13524585231198760.
     PubMed     Abstract available
     
     
     
380. VERCELLINO M, Costantini G, Cogoni M, Lequio L, et al
     Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
     Mult Scler. 2023 Sep 23:13524585231199031. doi: 10.1177/13524585231199031.
     PubMed     Abstract available
     
     
     
381. FREEDMAN DE, Krysko KM, Feinstein A
     Intimate partner violence and multiple sclerosis.
     Mult Scler. 2023 Sep 21:13524585231197926. doi: 10.1177/13524585231197926.
     PubMed     Abstract available
     
     
     
382. CARVAJAL R, Tur C, Martinez-Gomez X, Bollo L, et al
     A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
     Mult Scler. 2023 Sep 20:13524585231200303. doi: 10.1177/13524585231200303.
     PubMed     Abstract available
     
     
     
383. MORALES-RODRIGUEZ D, Anderson A, Nylander A, Hsu S, et al
     Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis.
     Mult Scler. 2023 Sep 16:13524585231197056. doi: 10.1177/13524585231197056.
     PubMed     Abstract available
     
     
     
384. KRAJNC N, Schmidbauer V, Leinkauf J, Haider L, et al
     Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis.
     Mult Scler. 2023 Sep 15:13524585231197954. doi: 10.1177/13524585231197954.
     PubMed     Abstract available
     
     
     
385. BOSE G, Healy BC, Barro C, Moreira Ferreira VF, et al
     Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis.
     Mult Scler. 2023 Sep 15:13524585231198751. doi: 10.1177/13524585231198751.
     PubMed     Abstract available
     
     
     
386. MARTIN SJ, Brand-Arzamendi K, Saab G, Muccilli A, et al
     GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis.
     Mult Scler. 2023 Sep 12:13524585231195861. doi: 10.1177/13524585231195861.
     PubMed     Abstract available
     
     
     
387. MOGHAVEM N, Castaneda GDR, Chatfield AJ, Amezcua L, et al
     The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review.
     Mult Scler. 2023 Sep 12:13524585231197275. doi: 10.1177/13524585231197275.
     PubMed     Abstract available
     
     
     
388. WANG Y, Bou Rjeily N, Koshorek J, Grkovski R, et al
     Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States.
     Mult Scler. 2023 Sep 12:13524585231196795. doi: 10.1177/13524585231196795.
     PubMed     Abstract available
     
     
     
389. BRUNO A, Buttari F, Dolcetti E, Azzolini F, et al
     Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
     Mult Scler. 2023 Sep 12:13524585231197928. doi: 10.1177/13524585231197928.
     PubMed     Abstract available
     
     
     
390. HAUSER SL, Zielman R, Das Gupta A, Xi J, et al
     Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
     Mult Scler. 2023 Sep 11:13524585231195346. doi: 10.1177/13524585231195346.
     PubMed     Abstract available
     
     
     
391. DEJONGE SR, DuBose NG, Pilutti LA, Motl RW, et al
     Arterial stiffness in persons with multiple sclerosis and controls: Does aerobic fitness account for group differences?
     Mult Scler. 2023 Sep 11:13524585231199030. doi: 10.1177/13524585231199030.
     PubMed     Abstract available
     
     
     
392. GABRIELLI M, Verderio C
     Exosomal profiling should be used to monitor disease activity in MS patients: Commentary.
     Mult Scler. 2023 Sep 7:13524585231195858. doi: 10.1177/13524585231195858.
     PubMed    
     
     
     
393. DELTOMBE M, van Pesch V
     Exosomal profiling should be used to monitor disease activity in MS patients: No.
     Mult Scler. 2023 Sep 7:13524585231195859. doi: 10.1177/13524585231195859.
     PubMed    
     
     
     
394. MYCKO MP
     Exosomal profiling should be used to monitor disease activity in MS patients: Yes.
     Mult Scler. 2023 Sep 7:13524585231195860. doi: 10.1177/13524585231195860.
     PubMed    
     
     
     
395. CARNERO CONTENTTI E
     Rectifying global inequities in neuromyelitis optica diagnosis and treatment: A critical view from Latin America.
     Mult Scler. 2023;29:1347-1348.
     PubMed    
     
     
     
396. BERHANU D, Leal Rato M, Messina S, Leite MI, et al
     The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD.
     Mult Scler. 2023;29:1250-1256.
     PubMed     Abstract available
     
     
     
397. CARNERO CONTENTTI E, Lopez PA, Tkachuk V, Vrech C, et al
     Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting.
     Mult Scler. 2023;29:1240-1249.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.